Background—Chagas disease remains a significant public health issue and a major cause
of morbidity and mortality in Latin America. Despite nearly 1 century of research, the …

Chagas cardiomyopathy is the most frequent and most severe manifestation of chronic
Chagas disease, and is one of the leading causes of morbidity and death in Latin America …

More than 100 years after the discovery of human American trypanosomiasis by Carlos
Chagas, our knowledge and management of the disease are profoundly changing …

Background and objectives The recent significant increase in the number of immigrants
entering the European Union from South and Central America means that chronic Chagas' …

Chagas disease (CD) is caused by the infection with the protozoan haemoflagellate
Trypanosoma cruzi. This disease is still a great menace to public health, and is largely …

Chagas disease is a neglected infectious disease in the tropics and an emerging health
problem in Europe and the USA. In the past decade, a link has been recorded between …

Quantitative real-time PCR (qPCR) is an accurate method to quantify Trypanosoma cruzi
DNA and can be used to follow-up parasitemia in Chagas disease (CD) patients undergoing …

Among the pathophysiological derangements operating in the chronic phase of Chagas
disease, parasite persistence is likely to constitute the main mechanism of myocardial injury …

BACKGROUND: Benznidazole is effective for treating acute and chronic (recently acquired)
Trypanosoma cruzi infection (Chagas' disease). Recent data indicate that parasite …

Background Prevention of chronic chagasic cardiomyopathy (CCC) by treating infected
populations with trypanocidal therapy (TT) remains a challenge. Despite a renewed …